

## A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- confirmed Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - have not been treated for PDAC - prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed at least 12 months ago - may not be able to do physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work -see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Inclusion criteria

---

**Exclusion Criteria:**

- history of brain metastases or leptomeningeal metastases - prior treatment with a CD73 antagonist or inhibitor - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Exclusion criteria

### Conditions & Interventions

**Interventions:**

Drug: Gemcitabine, Drug: Nab-paclitaxel, Drug: Placebo, Drug: Quemliclustat

**Conditions:**

Cancer

**Keywords:**

Metastatic Pancreatic Ductal Adenocarcinoma, pancreatic cancer, PDAC

### More Information

**Description:** The purpose of this study is to compare treatment with quemliclustat, nab-paclitaxel and gemcitabine to treatment with placebo (inactive drug), nab-paclitaxel and gemcitabine for people who have metastatic pancreatic cancer.

**Study Contact:** Kristen Nelson - [knelso65@fairview.org](mailto:knelso65@fairview.org)

**Principal Investigator:** Sunn Sunn Thaw

**Phase:** PHASE3

**IRB Number:** MMCORC090

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.